Chemesis International Inc. Begins Commercialization of QuickStrip™ Oral Thin Strips
Chemesis, Inc. (CSE: CSI) (OTC: CADMF) (FRA:CWAA)
Chemesis International Inc. Begins Commercialization of QuickStrip™ Oral Thin Strips
With the expanded manufacturing, Chemesis will launch distribution of the CBD QuickStrip™ Oral Thin Strips,
to retailers across the United States
June 13, 2019
Vancouver, BC – Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA: CWAA) (the “Company” or
“Chemesis”), announces it has begun commercialization of QuickStrip™Oral Thin Strips. The Company will
deliver CBD infused strips across the United States as well as THC & CBD infused strips in Puerto Rico.
The Natural Ventures facility houses the infrastructure required to manufacture, package and distribute
QuickStrip Oral Thin Strips. Chemesis will distribute Quick Strip through its subsidiary Natural Ventures
distribution network and existing relationships on the island.
As the Company continues to expand its manufacturing, Chemesis will look to add additional
infrastructure for its Quick Strip Oral Thin Strips in California. In anticipation of federally changing CBD
regulations, Chemesis has begun signing distribution agreements in the m ainland United States for CBD
infused Quick Strip products to ensure the Company maintains a first mover advantage by forming
distribution channels and partnerships that will gain market share. The proprietary drug delivery
technology is infused with CBD, THC and other cannabinoids.
The Rapid Dose Therapeutics QuickStrip delivery system is a true sublingual delivery device for THC, CBD
and other cannabinoids. Furthermore, Quick Strip is conducting controlled trials to further demonstrate
QuickStrip effectiveness and consistent onset. Chemesis believes this technology is at the forefront of
sublingual delivery systems and will expand its efforts to bring it to market.
“We believe our partnership with Rapid Dose Therapeutics in Puerto Rico will bring an incredible amount
of value to the Company,” said CEO of Chemesis, Edgar Montero. “The innovative delivery system that is
Quick, Convenient, Precise, and D iscreet™ will give consumers the ability to quickly absorb an accurate
dose of THC or CBD. The Company believes that QuickStrip will build significant market share as a n
effective method of sublingually administering cannabinoids.”
On Behalf of The Board of Directors
Edgar Montero
CEO and Director
About Chemesis International Inc.
Chemesis International Inc. is a vertically integrated U.S. Multi -State operator with International
operations in Puerto Rico, and Colombia.
The Company focuses on prudent capital allocation to ensure it maintains a first mover advantage as it
enters new markets and is committed to differentiate itself by deploying resources in markets with major
Chemesis, Inc. (CSE: CSI) (OTC: CADMF) (FRA:CWAA)
opportunities. The Company operates a portfolio of brands which cater to a wide community of cannabis
consumers, with focus on quality and consistency.
Chemesis has facilities in both Puerto Rico and California, and is in the process of constructing a GMP
certified facility in Colombia. Chemesis’ Puerto Rico operations are licensed to operate 100,000 ft 2 of
cultivation, and 35,000 ft 2 of manufacturing floor spa ce. The Company is positioned to win additional
licenses in highly competitive merit-based US states, and will expand its footprint to ensure it maintains a
first mover advantage.
Investor Relations:
1 (604) 398-3378
Social Media:
Chemesis.facebook
Chemesis.twitter
Chemesis.instagram
DesertZen.instagram
Jay&SB.instagram
Forward-Looking Information: This news release contains "forward -looking information" within the meaning of
applicable securities laws relating to statements regarding the Company's business, products and future of the
Company’s business, its product offerings and plans for sales and marketing, including finalizing an acquisition in
Colombia. Although the Company believes that the expecta tions reflected in the forward -looking information are
reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to
place undue reliance on forward -looking information. Such forward -looking statements are subject to risks and
uncertainties that may cause actual results, performance and developments to differ materially from those
contemplated by these statements depending on, among other things, the risks that the Company's products and
plan will vary from those stated in this news release and the Company may not be able to carry out its business plans
as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update
any forward-looking statements or forward-looking information in this news release. Although the Company believes
that the expectations reflected in the forward -looking information are reasonable, there can be no assurance that
such expectations will prove to be correct and makes no reference to profitability based on sales reported. The
statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release